Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 585,762
  • Shares Outstanding, K 67,562
  • Annual Sales, $ 7,360 K
  • Annual Income, $ -52,090 K
  • 60-Month Beta 0.32
  • Price/Sales 80.65
  • Price/Cash Flow N/A
  • Price/Book 2.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.26
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.51 +51.72%
on 11/11/19
8.90 -6.07%
on 12/10/19
+2.73 (+48.49%)
since 11/08/19
3-Month
4.50 +85.78%
on 10/10/19
8.90 -6.07%
on 12/10/19
+3.05 (+57.44%)
since 09/10/19
52-Week
3.25 +157.23%
on 01/30/19
12.50 -33.12%
on 12/12/18
-2.59 (-23.65%)
since 12/10/18

Most Recent Stories

More News
AC Immune to Present at Jefferies 2019 London Healthcare Conference

AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London...

LLY : 120.65 (+0.34%)
ACIU : 8.36 (-3.58%)
5 Biotech Stocks Set to Beat Q3 Earnings Estimates

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

ASND : 108.00 (+1.96%)
SAGE : 63.29 (+1.01%)
NGM : 17.50 (+5.17%)
EYEN : 3.44 (-3.10%)
ACIU : 8.36 (-3.58%)
Linde (LIN) to Report Q3 Earnings: What's in the Cards?

Favorable industrial production in the United States is likely to have favored Linde's (LIN) Q3 earnings.

FNV : 98.76 (+1.73%)
LIN : 203.95 (-0.67%)
ACIU : 8.36 (-3.58%)
CHRA : 2.24 (+1.36%)
AC Immune Hosts Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

Company Provides Key Updates on Tau Pipeline Candidates

ACIU : 8.36 (-3.58%)
AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACIU : 8.36 (-3.58%)
AC Immune to Host Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it will host a key opinion leader (KOL)...

ACIU : 8.36 (-3.58%)
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

ABBV : 86.56 (+0.14%)
LLY : 120.65 (+0.34%)
ALEC : 19.55 (-0.41%)
ACIU : 8.36 (-3.58%)
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

ITCI : 12.25 (+6.06%)
VTVT : 1.51 (+0.67%)
INMB : 4.77 (-2.77%)
ACIU : 8.36 (-3.58%)
ALEC : 19.55 (-0.41%)
SAVA : 1.65 (-1.20%)
AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson's Disease Diagnostic Imaging Agent

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced The Michael J. Fox Foundation for Parkinson's...

ACIU : 8.36 (-3.58%)
AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update

AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced its business and clinical plan and strategy,...

ACIU : 8.36 (-3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ACIU with:

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

2nd Resistance Point 9.09
1st Resistance Point 8.73
Last Price 8.36
1st Support Level 8.17
2nd Support Level 7.97

See More

52-Week High 12.50
Fibonacci 61.8% 8.97
Last Price 8.36
Fibonacci 50% 7.88
Fibonacci 38.2% 6.78
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar